Physician profile
Samar Mumtaz
NPI 1346403243
$1,998.05
in general payments reported to CMS, 2019-2025
31 companies · $610 in 2025
The $610 reported for 2025 was more than what 77% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $29.92 · 2022: $351 · 2023: $409 · 2024: $598 · 2025: $610.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,617.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,617.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $323.05 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $268.02 | 2022-2025 | Mounjaro, Zepbound, Trulicity |
| Pfizer INC. | $186.23 | 2022-2025 | |
| Abbvie INC. | $185.58 | 2022-2025 | |
| Glaxosmithkline, LLC. | $118.11 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $117.67 | 2022-2025 | Farxiga, Breztri, Airsupra |
| Aimmune Therapeutics, INC. | $109.85 | 2024-2025 | Zenpep |
| Inspire Medical Systems, INC. | $77.52 | 2024 | Inspire |
| Amgen INC. | $68.67 | 2023-2025 | Repatha, Otezla, Repatha |
| Abbott Laboratories | $66.13 | 2022-2024 | Freestyle Libre 2 |
| Ucb, INC. | $47.65 | 2021-2023 | Nayzilam |
| Biohaven Pharmaceutical Holding Company LTD. | $37.92 | 2022 | |
| Astellas Pharma US INC | $34.18 | 2025 | Veozah |
| Ethicon INC. | $34.02 | 2025 | Monarch Platform |
| Dexcom, INC. | $27.66 | 2023 | Dexcom G6 Transmitter |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $25.23 | 2025 | |
| Shield Therapeutics INC | $23.19 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.09 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20.93 | 2023 | Trintellix |
| Ani Pharmaceuticals, INC. | $20.46 | 2024 | Purified Cortrophin Gel |
| Boston Scientific Corporation | $20.21 | 2025 | General - Pain Management |
| Otsuka America Pharmaceutical, INC. | $20.12 | 2025 | Rexulti |
| Esperion Therapeutics, INC. | $18.06 | 2025 | Nexletol |
| Biogen, INC. | $17.61 | 2022 | |
| Lucid Diagnostics INC. | $17.45 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $17.24 | 2025 | Camzyos |
| Endo Pharmaceuticals INC. | $16.28 | 2021 | |
| Vivaquant INC, Dba Rhythm Express | $15.86 | 2024 | Rhythm Express |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.92 | 2024 | Xifaxan |
| Exact Sciences Corporation | $13.93 | 2024 | Cologuard Collection Kit |
| Alnylam Pharmaceuticals INC. | $13.21 | 2024 | Onpattro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samar Mumtaz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.